The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery

Gary Gintant; Bernard Fermini; Norman Stockbridge; David Strauss

doi:10.1016/j.stem.2017.06.005

The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery

Cell Stem Cell. 2017 Jul 6;21(1):14-17. doi: 10.1016/j.stem.2017.06.005.

Authors

Gary Gintant¹, Bernard Fermini², Norman Stockbridge³, David Strauss⁴

Affiliations

¹ Department of Integrative Pharmacology (ZR13), Integrated Science and Technology, AbbVie, Building AP-9A LL, 1 North Waukegan Road, North Chicago, IL 60064-6118, USA. Electronic address: [email protected].
² Coyne Scientific, 58 Edgewood Avenue NE, Atlanta, GA 30303, USA.
³ Division of Cardiovascular and Renal Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.
⁴ Division of Applied Regulatory Science, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA.

PMID: 28686863
DOI: 10.1016/j.stem.2017.06.005

Abstract

Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.

Publication types

Review

MeSH terms

Arrhythmias, Cardiac / drug therapy*
Arrhythmias, Cardiac / metabolism*
Arrhythmias, Cardiac / pathology
Drug Evaluation, Preclinical / methods*
Humans
Induced Pluripotent Stem Cells / metabolism*
Induced Pluripotent Stem Cells / pathology
Myocytes, Cardiac / metabolism*
Myocytes, Cardiac / pathology